Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bakuchiol in Post-inflammatory Hyperpigmentation
NCT06833996Completed
- Sponsor
- Henry Ford Health
- Start
- Feb 2016
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Randomised, double-blind trial of bakuchiol in Post-inflammatory hyperpigmentation (PIH), sponsored by Henry Ford Health. Primary endpoint: Degree of hyperpigmentation at 56 days. Started Feb 2016; status: completed.
02
Drugs
bakuchiol
03
Conditions
Post-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on NCT06833996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833996.